Septerna, Inc.
NASDAQ:SEPNBiotechnology
-$0.73 today
- Market cap
- $1.88B
- Beta
- 2.38
- P/E (TTM)
- -43.6
- EPS (TTM)
- -$0.81
Volume 0.30M
Average 0.32M
SEPN Net Debt
Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.
Septerna, Inc.NASDAQ: SEPN
Net Debt · Q3 FY2026 · quarter ended Sep 2026
Net debt remains negative
Q3 FY2026 net debt was -$145.13M, compared with -$295.88M a year earlier.
Context
- Net debt amounted to 23.4% of total assets at the end of Q3 FY2026, down 25.3 pp from a year earlier.
- Net debt grew in size in 2 of the last 3 fiscal years.
What to watch
Whether net debt keeps rising in the next quarterly balance sheet after a +50.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Debt history
USD · from the balance sheet
- Latest · FY2025
- (97.1M) USD
- Year-over-year change
- +54.4%
| Period | Period end | Net Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (97.1M) | +54.4% |
| FY2024 | 2024-12-31 | (212.72M) | -180.2% |
| FY2023 | 2023-12-31 | (75.92M) | -153.9% |
| FY2022 | 2022-12-31 | (29.9M) | — |
Net Debt vs competitors
How SEPN compares with its peers on the latest reported figures
- SEPN's Sep 2026 net debt of -$145.13M is the 5th highest of the 7 companies compared; the peer median is -$128.81M.
- Its year-over-year change of +50.9% is the highest of 6, against a peer median of -55.5%.
- Net debt amounts to 23.4% of total assets for SEPN, versus a peer median of 32.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | -$43.45M | -55.5% | — | 93.7% | |
| Mar 2026 | -$98.09M | -217.1% | — | 99.3% | |
KLRAKailera Therapeutics, Inc. | Jun 2026 | -$120.09M | — | — | 9.9% |
| Mar 2026 | -$137.54M | +48.8% | — | 32.8% | |
SEPNSepterna, Inc. | Sep 2026 | -$145.13M | +50.9% | — | 23.4% |
MBXMBX Biosciences, Inc. Common Stock | Sep 2026 | -$158.4M | +28.8% | — | 31.6% |
| Jun 2026 | -$266.41M | -91.2% | — | 18.7% | |
| Peer median (excluding SEPN) | -$128.81M | -55.5% | — | 32.2% | |
Competitors are the stored peer set for SEPN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Septerna, Inc.
NASDAQ:SEPN
Intrinsic Alpha fair value
Locked
Current Price
$39.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.